dihydroequilin has been researched along with fulvestrant in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Awad, EM; Bochkov, VN; Demyanets, S; Dietrich, W; Hohensinner, PJ; Huber, K; Kastl, SP; Kaun, C; Maurer, G; Pfaffenberger, S; Rega, G; Speidl, WS; Tschugguel, W; Weiss, TW; Wojta, J | 1 |
1 other study(ies) available for dihydroequilin and fulvestrant
Article | Year |
---|---|
The estrogen metabolite 17beta-dihydroequilenin counteracts interleukin-1alpha induced expression of inflammatory mediators in human endothelial cells in vitro via NF-kappaB pathway.
Topics: Anti-Inflammatory Agents; Base Sequence; Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Endothelial Cells; Equilin; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Fulvestrant; Humans; Interleukin-1; Interleukin-6; Interleukin-8; Molecular Sequence Data; NF-kappa B; RNA, Messenger | 2006 |